Table 4.
Test doses improved antimicrobial therapy in the post-guideline period (n=183)
| Antibiotic or class of antibiotic No.( %) | Before test dose | After test dose | P Value* |
|---|---|---|---|
| Penicillins † | 3 (2) | 35 (19) | <0.001 |
| Piperacillin-tazobactam | 4 (2) | 2 (1) | >0.5 |
| Cephalosporins ‡ | |||
| 1st generation | 1 (0.6) | 18 (10) | <0.001 |
| 3rd generation | 9 (5) | 54 (30) | <0.001 |
| 4th generation | 12 (7) | 58 (32) | <0.001 |
| Aztreonam | 21 (12) | 1 (0.6) | <0.001 |
| Carbapenem | 18 (10) | 11 (6) | 0.21 |
| Clindamycin | 3 (2) | 2 (1) | >0.5 |
| Daptomycin | 2 (1) | 2 (1) | >0.5 |
| Fluoroquinolone | 28 (15) | 6 (3) | <0.001 |
| Gentamycin | 11 (6) | 2 (1) | 0.004 |
| Linezolid | 7 (4) | 4 (2) | 0.45 |
| Vancomycin | 125 (68) | 68 (37) | <0.001 |
*
McNemar's test
†
Other than piperacillin-tazobactam, considered separately due to its broad coverage
‡
No patients were treated with 2nd generation cephalosporins